Novartis AG (NOVN):企業の財務・戦略的SWOT分析

◆英語タイトル:Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH24864FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:95
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Novartis AG (NOVN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Mar 05,2021: Novartis announces change to the Executive Committee
Feb 17,2021: Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
Feb 12,2021: Novartis: Expanding CAR-T manufacturing in Australia
Feb 11,2021: Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences
Jan 26,2021: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Novartis AG – Key Facts
Novartis AG – Key Employees
Novartis AG – Key Employee Biographies
Novartis AG – Major Products and Services
Novartis AG – History
Novartis AG – Company Statement
Novartis AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Novartis AG – Business Description
Business Segment: Innovative Medicines
Overview
Performance
Key Stats
Business Segment: Sandoz
Overview
Performance
Key Stats
Geographical Segment: Asia/Africa/Australasia
Performance
Performance
Geographical Segment: Canada and Latin America
Performance
Geographical Segment: Europe
Performance
Geographical Segment: The US
Performance
R&D Overview
Novartis AG – Corporate Strategy
Novartis AG – SWOT Analysis
SWOT Analysis – Overview
Novartis AG – Strengths
Novartis AG – Weaknesses
Novartis AG – Opportunities
Novartis AG – Threats
Novartis AG – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novartis AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 05, 2021: Novartis announces change to the Executive Committee
Feb 17, 2021: Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
Feb 12, 2021: Novartis: Expanding CAR-T manufacturing in Australia
Feb 11, 2021: Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences
Jan 26, 2021: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020
Jan 26, 2021: Credence MedSystems receives a strategic investment from one of the world’s leading pharmaceutical companies
Jan 26, 2021: Novartis ranks second in 2021 Access to Medicine Index
Jan 19, 2021: Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa
Dec 08, 2020: RetinAI announces collaboration with Novartis to provide artificial intelligence solutions in ophthalmology
Nov 24, 2020: Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Novartis AG, Key Facts
Novartis AG, Key Employees
Novartis AG, Key Employee Biographies
Novartis AG, Major Products and Services
Novartis AG, History
Novartis AG, Subsidiaries
Novartis AG, Joint Venture
Novartis AG, Key Competitors
Novartis AG, Ratios based on current share price
Novartis AG, Annual Ratios
Novartis AG, Annual Ratios (Cont...1)
Novartis AG, Annual Ratios (Cont...2)
Novartis AG, Interim Ratios
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novartis AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Novartis AG (NOVN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Colby Pharmaceutical Co-製薬・医療分野:企業M&A・提携分析
    Summary Colby Pharmaceutical Company (Colby Pharma) is a biopharma company that focuses on the development of safe and effective small molecule analgesic, anti-inflammatory drug, and immunobiologic products. Its product portfolio includes Oral small molecule analgesics CPC-123 & CPC-111 for post-sur …
  • Warimpex Finanz- und Beteiligungs AG:企業の戦略・SWOT・財務情報
    Warimpex Finanz- und Beteiligungs AG - Strategy, SWOT and Corporate Finance Report Summary Warimpex Finanz- und Beteiligungs AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Genuine Parts Company (GPC):企業の財務・戦略的SWOT分析
    Genuine Parts Company (GPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Petrel Resources Plc (PET):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrel Resources Plc (Petrel Resources) is an oil and gas company that provides exploration and production of crude oil and natural gas across Iraq. The company provides areas of operations such as Luhais and Subba in Southern Iraq, Tano Basin in Ghana, Porcupine Basin in Ireland, and others …
  • Spineology Inc:医療機器:M&Aディール及び事業提携情報
    Summary Spineology Inc (Spineology) is a medical device company that develops and designs spinal implants. The company offers products such as pedicular fixation system, interbody fusion system, deployable grafting system, amniotic fixation system, allografts, retractor system, liquid tissue matrix, …
  • ZoomMed Inc (ZMD):医療機器:M&Aディール及び事業提携情報
    Summary ZoomMed Inc (ZoomMed) is a technical service provider that offers web solutions for medical sectors. The company’s product includes ZoomMed Network, ZRx Prescriber, PraxisLab, and EvPsych. It builds and operates a clinical information exchange platform between physicians and specialists, pat …
  • OncoSec Medical Inc (ONCS)-医療機器分野:企業M&A・提携分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through i …
  • Cellnovo Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Cellnovo Ltd (Cellnovo), formerly Starbridge Systems Ltd is a provider of conventional diabetes care technology solutions. The company offers mobile diabetes management systems such as insulin patch pump, cellular-enabled wireless touchscreen handset with integrated blood glucose meter, acti …
  • Turner & Townsend Plc:企業の戦略的SWOT分析
    Turner & Townsend Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Helix Energy Solutions Group Inc (HLX):企業の財務・戦略的SWOT分析
    Summary Helix Energy Solutions Group Inc (Helix Energy) is an oil and gas company that provides offshore energy services. The company provides well intervention, subsea engineering and contracting services. Its well intervention services comprise riserless intervention and riser based operations, st …
  • Aemetis Inc (AMTX):企業の財務・戦略的SWOT分析
    Summary Aemetis Inc (Aemetis) formerly AE Biofuels Inc is a renewable fuels and biochemicals company that produces advanced fuels and chemicals. The company’s products include biochemicals, renewable fuels, ethanol, ethanol co-products, glycerin, biodiesel, and edible oils, among others. It also pro …
  • Federal-Mogul Holdings LLC:企業の戦略的SWOT分析
    Federal-Mogul Holdings LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Invenra Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Invenra Inc (Invenra) is a biotechnology company that discovers and develops multispecific antibodies for immuno-oncology. The company’s pipeline products include t-cell redirecting b-bodies, OX40 agonist, treg depleter SNIPER and exelixis B-Body. Its B-Body and SNIPER technologies are used …
  • AFT Pharmaceuticals Pty Ltd-製薬・医療分野:企業M&A・提携分析
    Summary AFT Pharmaceuticals Pty Ltd (AFT Pharmaceuticals) is a manufacturer and distributor medical products. The company provides prescription and non-prescription products. Its products include moisturizers, calcium supplements, scalp ointments, eye drops, cracked heel creams, iron and folic acid …
  • Arkray Inc:企業の製品パイプライン分析2018
    Summary Arkray Inc (Arkray), formerly KDK Corp is a medical device company that offers diagnostic products. The company offers diagnostic products and equipments for diabetes diagnosis and urinalysis applications. Its products comprise automatic glycohemoglobin analyzer for diabetes, automated analy …
  • Exide Technologies:企業の戦略・SWOT・財務分析
    Exide Technologies - Strategy, SWOT and Corporate Finance Report Summary Exide Technologies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Net One Systems Co Ltd (7518):企業の財務・戦略的SWOT分析
    Net One Systems Co Ltd (7518) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • InspireMD Inc (NSPR):企業の製品パイプライン分析
    Summary InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for us …
  • Ulthera Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ulthera Inc (Ulthera), a subsidiary of Merz Pharma GmbH & Co KgaA is a medical device company that develops and commercializes technologies for aesthetic and medical applications by using its therapeutic ultrasound platform technologies. The company’s therapeutic ultrasound platform technolo …
  • Sirius XM Radio Inc. (SIRI):企業の財務・戦略的SWOT分析
    Sirius XM Radio Inc. (SIRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆